随机安慰剂对照试验及Meta分析显示昂丹司琼对腹泻型肠易激综合征有益:TRITON试验
TRITON试验为12周平行组、随机双盲、安慰剂对照试验,计划纳入400例腹泻型肠易激综合征(IBS-D)患者,实际随机80例,评估昂丹司琼4 mg每日一次(可滴定至8 mg每日三次)的疗效。主要终点未达统计学显著,但昂丹司琼改善粪便稠度并延长全胃肠转运时间;Meta分析(327例)显示昂丹司琼在FDA复合终点和粪便应答上优于安慰剂,但腹痛应答无显著差异。
要点
- 本试验主要终点未达统计学显著:昂丹司琼组15/37(40.5%)vs 安慰剂组12/43(27.9%),p=0.19。
- 昂丹司琼改善粪便稠度(校正均差-0.7,95%CI -1.0至-0.3,p<0.001)。
- Meta分析示昂丹司琼在FDA复合终点(RR 0.86,95%CI 0.75-0.98,NNT=9)和粪便应答(RR 0.65,95%CI 0.52-0.82,NNT=5)优于安慰剂。
核心结论
- 本试验因样本量小主要终点未达统计学显著,但与其他类似试验 pooled Meta分析提示昂丹司琼改善粪便稠度、减少稀便天数和便急。
研究设计与样本
- 12周平行组、随机双盲、安慰剂对照试验,计划纳入400例IBS-D患者,实际随机80例。
- 干预为昂丹司琼4 mg每日一次,可滴定至8 mg每日三次;主要终点为FDA复合终点应答者百分比。
- 对文献复习后,将本试验与其他安慰剂对照试验结果 pooled 进行Meta分析,估计相对风险(RR)、95%置信区间(CI)和需治疗人数(NNT)。
主要发现
- 意向性分析中,昂丹司琼组15/37(40.5%;95%CI 24.7%-56.4%)达到主要终点,安慰剂组12/43(27.9%;95%CI 14.5%-41.3%),p=0.19。
- 昂丹司琼较安慰剂改善粪便稠度(校正均差-0.7;95%CI -1.0至-0.3,p<0.001)。
- 昂丹司琼使第12周与基线间全胃肠转运时间增加,平均(SD)差值为3.8(9.1)小时,安慰剂组为-2.2(10.3)小时,p=0.01。
- Meta分析纳入本试验及两项类似试验共327例患者,显示昂丹司琼在FDA复合终点优于安慰剂(症状未缓解的RR=0.86;95%CI 0.75-0.98,NNT=9),粪便应答优于安慰剂(RR=0.65;95%CI 0.52-0.82,NNT=5),腹痛应答无显著差异(RR=0.95;95%CI 0.74-1.20)。
局限性
- 本试验样本量小,主要终点未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ondansetron may be beneficial in irritable bowel syndrome with diarrhoea (IBS-D). AIM: To conduct a 12-week parallel group, randomised, double-blind, placebo-controlled trial of ondansetron 4 mg o.d. (titrated up to 8 mg t.d.s.) in 400 IBS-D patients. PRIMARY ENDPOINT: % responders using the Food and Drug Administration (FDA) composite endpoint. Secondary and mechanistic endpoints included stool consistency (Bristol Stool Form Scale) and whole gut transit time (WGTT). After literature review, results were pooled with other placebo-controlled trials in a meta-analysis to estimate relative risks (RR), 95% confidence intervals (CIs) and number needed to treat (NNT). RESULTS: Eighty patients were randomised. On intention-to-treat analysis, 15/37 (40.5%; 95% CI 24.7%-56.4%) met the primary endpoint on ondansetron versus 12/43 (27.9%; 95% CI 14.5%-41.3%) on placebo (p = 0.19). Ondansetron improved stool consistency compared with placebo (adjusted mean difference - 0.7; 95% CI -1.0 to-0.3, p < 0.001). Ondansetron increased WGTT between baseline and week 12 (mean (SD) difference 3.8 (9.1) hours, versus placebo -2.2 (10.3) hours, p = 0.01). Meta-analysis of 327 patients from this, and two similar trials, demonstrated ondansetron was superior to placebo for the FDA composite endpoint (RR of symptoms not responding = 0.86; 95% CI 0.75-0.98, NNT = 9) and stool response (RR = 0.65; 95% CI 0.52-0.82, NNT = 5), but not abdominal pain response (RR = 0.95; 95% CI 0.74-1.20). CONCLUSIONS: Although small numbers meant the primary endpoint was not met in this trial, when pooled with other similar trials meta-analysis suggests ondansetron improves stool consistency and reduces days with loose stool and urgency. Trial registration - http://www.isrctn.com/ISRCTN17508514.
引用
- Gunn D, Topan R, Barnard L, et al. Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial. Aliment Pharmacol Ther. 2023. PMID: 36866724. doi:10.1111/apt.17426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。